Monte Rosa Therapeutics
GLUE
Insidertransaktionen und Aktienkurs 2024-2026
Alle Insidertrades bei Monte Rosa Therapeutics
| Datum |
Typ |
Insider |
Position |
Ø-Preis |
Volumen |
|
16.7.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
23,2 $ |
220.219 $ |
|
15.7.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
23,4 $ |
101.730 $ |
|
6.7.2026
|
Verkauf |
Townson, Sharon |
Chief Scientific Officer |
23,7 $ |
139.849 $ |
|
30.6.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
24,5 $ |
132.472 $ |
|
29.6.2026
|
Verkauf |
Manning, Anthony M. |
Aufsichtsrat |
23,1 $ |
231.100 $ |
|
29.6.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
23,0 $ |
137.700 $ |
|
24.6.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
21,4 $ |
642.681 $ |
|
23.6.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
20,0 $ |
43.500 $ |
|
23.6.2026
|
Verkauf |
Townson, Sharon |
Chief Scientific Officer |
20,0 $ |
60.000 $ |
|
23.6.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
20,2 $ |
239.522 $ |
|
17.6.2026
|
Verkauf |
Townson, Sharon |
Chief Scientific Officer |
19,0 $ |
57.000 $ |
|
17.6.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
19,0 $ |
41.344 $ |
|
1.6.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
19,6 $ |
106.253 $ |
|
29.5.2026
|
Verkauf |
Townson, Sharon |
Chief Scientific Officer |
19,9 $ |
119.220 $ |
|
27.5.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
20,0 $ |
43.500 $ |
|
22.5.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
19,0 $ |
41.344 $ |
|
21.5.2026
|
Verkauf |
Manning, Anthony M. |
Aufsichtsrat |
18,0 $ |
180.100 $ |
|
1.5.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
18,9 $ |
103.447 $ |
|
14.4.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
17,6 $ |
141.125 $ |
|
9.4.2026
|
Verkauf |
Nickson, Philip |
Chief Business & Legal Officer |
17,7 $ |
103.413 $ |
|
4.3.2026
|
Verkauf |
Dunn, Edmund |
Principal Accounting Officer |
18,0 $ |
2.496 $ |
|
2.3.2026
|
Verkauf |
Dunn, Edmund |
Principal Accounting Officer |
17,5 $ |
9.380 $ |
|
2.3.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
17,9 $ |
97.974 $ |
|
27.2.2026
|
Verkauf |
Dunn, Edmund |
Principal Accounting Officer |
18,1 $ |
455.506 $ |
|
23.2.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
19,5 $ |
179.161 $ |
|
7.1.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
23,9 $ |
128.372 $ |
|
5.1.2026
|
Verkauf |
Townson, Sharon |
Chief Scientific Officer |
15,2 $ |
47.861 $ |
|
5.1.2026
|
Verkauf |
Janku, Filip |
Chief Medical Officer |
15,2 $ |
47.861 $ |
|
5.1.2026
|
Verkauf |
Warmuth, Markus |
President & CEO |
15,2 $ |
153.748 $ |
|
5.1.2026
|
Verkauf |
Dunn, Edmund |
Principal Accounting Officer |
15,2 $ |
15.762 $ |
|
5.1.2026
|
Verkauf |
Champoux, Jennifer |
Chief Operating Officer |
15,2 $ |
39.882 $ |
|
5.1.2026
|
Verkauf |
Nickson, Philip |
Chief Business & Legal Officer |
15,2 $ |
47.861 $ |
|
3.6.2025
|
Verkauf |
Dunn, Edmund |
Principal Accounting Officer |
4,4 $ |
9.174 $ |
|
24.3.2025
|
Kauf |
Leo, Chandra P. |
Aufsichtsrat |
5,8 $ |
58.383 $ |
|
29.10.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
9,2 $ |
621.801 $ |
|
28.10.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
9,7 $ |
869.240 $ |
|
20.9.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
6,5 $ |
7.395.203 $ |
|
13.9.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
6,2 $ |
57.100 $ |
|
12.9.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
6,0 $ |
96.309 $ |
|
11.9.2024
|
Verkauf |
Versant Venture Capital Vi, L.p. |
Zehn-Prozent-Eigentümer |
6,0 $ |
3.251.382 $ |
Alle Angaben ohne Gewähr! Keine Empfehlung/Beratung! © U.S. Securities and Exchange Commission (SEC)
Kostenlose Updates per Mail
Bestätige noch deine Email-Adresse